Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hemal Mehta

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Clinical & Experimental Ophthalmology|May 9, 2020
Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! RegistryAnne C Biechl, Sanjeeb Bhandari, Vuong Nguyen, et al.
American Journal of Physiology. Heart and Circulatory Physiology|July 14, 2018
Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in miceQing Qin, Hemal Mehta, Kelvin Yen, et al.
Investigative Ophthalmology & Visual Science|March 30, 2013
Repeatability and reproducibility of choroidal vessel layer measurements in diabetic retinopathy using enhanced depth optical coherence tomographyDawn A Sim, Pearse A Keane, Hemal Mehta, et al.
Ophthalmology and Therapy|May 17, 2017
Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRAYit Yang, Louise Downey, Hemal Mehta, et al.
Ophthalmology|January 15, 2020
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! RegistrySanjeeb Bhandari, Vuong Nguyen, Samantha Fraser-Bell, et al.
Acta Ophthalmologica|November 16, 2020
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! RegistryPierre-Henry Gabrielle, Vuong Nguyen, Sanjeeb Bhandari, et al.
BMJ Open Ophthalmology|October 21, 2025
A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN StudyLong T Phan, Thomas Hong, John H Chang, et al.
Scientific Reports|March 14, 2024
Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registryGonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, et al.
The British Journal of Ophthalmology|August 3, 2021
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedemaElisa E Cornish, Kelvin Yc Teo, Mark C Gillies, et al.
American Journal of Ophthalmology|October 7, 2014
Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiographyCecilia S Lee, Aaron Y Lee, Dawn A Sim, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Clinical & Experimental Ophthalmology|May 9, 2020
Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: Data from the Fight Retinal Blindness! RegistryAnne C Biechl, Sanjeeb Bhandari, Vuong Nguyen, et al.
American Journal of Physiology. Heart and Circulatory Physiology|July 14, 2018
Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in miceQing Qin, Hemal Mehta, Kelvin Yen, et al.
Investigative Ophthalmology & Visual Science|March 30, 2013
Repeatability and reproducibility of choroidal vessel layer measurements in diabetic retinopathy using enhanced depth optical coherence tomographyDawn A Sim, Pearse A Keane, Hemal Mehta, et al.
Ophthalmology and Therapy|May 17, 2017
Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRAYit Yang, Louise Downey, Hemal Mehta, et al.
Ophthalmology|January 15, 2020
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! RegistrySanjeeb Bhandari, Vuong Nguyen, Samantha Fraser-Bell, et al.
Acta Ophthalmologica|November 16, 2020
Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! RegistryPierre-Henry Gabrielle, Vuong Nguyen, Sanjeeb Bhandari, et al.
BMJ Open Ophthalmology|October 21, 2025
A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN StudyLong T Phan, Thomas Hong, John H Chang, et al.
Scientific Reports|March 14, 2024
Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registryGonzaga Garay-Aramburu, Adrian Hunt, Carolina Arruabarrena, et al.
The British Journal of Ophthalmology|August 3, 2021
Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedemaElisa E Cornish, Kelvin Yc Teo, Mark C Gillies, et al.
American Journal of Ophthalmology|October 7, 2014
Reevaluating the definition of intraretinal microvascular abnormalities and neovascularization elsewhere in diabetic retinopathy using optical coherence tomography and fluorescein angiographyCecilia S Lee, Aaron Y Lee, Dawn A Sim, et al.
Pageof 9